Morgan Stanley reported better-than-expected Q3 2026 earnings and revenue, driven by strong Institutional Securities performance. Despite the positive results, several analysts lowered their price targets for MS stock, leading to a slight share price dip.
Morgan Stanley delivered a strong Q3 2026 performance, exceeding analyst expectations for both earnings and revenue. This positive financial outcome was largely attributed to robust activity in its Institutional Securities division, particularly in equity trading and M&A. However, the filing highlights a curious market reaction: despite the beat, several prominent analysts, including those from Keefe, Bruyette & Woods and Evercore ISI Group, subsequently lowered their price targets for MS. This suggests that while current performance is strong, analysts may be factoring in broader market conditions, future growth prospects, or valuation concerns that temper their long-term outlook. For traders, the short-term implication is a potential downward pressure on MS stock, as seen by the 1.1% dip, despite the strong earnings report. The key risk is that analyst sentiment could continue to weigh on the stock, even with solid fundamentals.